Moleculin Enters Strategic Collaboration to Develop Immune Stimulation Drug


 
 
02:07 10/12/2017

MBRX , a clinical stage company that concentrates on the advancement of any-cancer drug candidates, announced that it has entered into an agreement to work together with the University of Bergen to expand research on inhibition of brain metastasis by Moleculin's pre-clinical drug WP1066 and its unique ability to increase immune system response to cancer and suppression of tumor cell proliferation and survival.

"We've seen promising evidence that WP1066 has potent anticancer effects in animal tumor models due to its unique mode of action," commented Walter Klemp, Chairman and CEO of Moleculin. "WP1066 is well known for its ability to block the expression of the key oncogenic transcription factors that promote tumor growth and suppress immune system responses. As such, we believe WP1066 has promising potential to stimulate patients' natural immune response against tumors."

Mr. Klemp continued, "We announced last month a separate collaboration with the University of Bergen in Norway on WP1122 for brain tumors. The WP1066 project will be led by Dr. Frits Alan Thorsen and may provide critical insight on WP1066, which we anticipate will be in clinical trials soon."

Some of their anti-cancer drug candidates are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center. MDRX  has a leading product candidate called Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML.

MDRX  also has two preclinical small molecule portfolios in development, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors.


This article has been provided by a Chasing Markets contributor. All content submitted by this author represent their personal opinions, and should be considered as such for entertainment purpose only. All opinions expressed are those of the writer, and may not necessarily represent fact, opinions, or bias of Chasing Markets.
Most Read